



Presentations at **2026 AACR Annual Meeting**

April 17-22, 2026

*All times are in PT

Presentation	Author	Session/Time
Sunday, April 19, 2026		
Tumor genomic features and postsurgical ctDNA status in patients with stage I-IV uterine cancer (Presentation number 1144)	Tara Berman, MD, MS	Poster Session: Liquid Biopsies: Circulating Nucleic Acids 1 – 2:00 pm - 5:00 pm PT (Section 44)
Targeting cyclin K-CDK12 synergizes with ATR inhibition by limiting RPA chromatin loading in triple-negative breast cancer (Presentation number 251)	Eun-Bee Choi, PhD	Poster Session: DNA Damage and Repair 1 – 2:00 pm - 5:00 pm PT (Section 11)
Exploring the role of catecholamine signaling in CD8+ T cell immunity to neuroblastoma (Presentation number 178)	Mark Chudnovsky	Poster Session: Immune Cell Biology and Tumor-Immune Crosstalk – 2:00 pm - 5:00 pm PT (Section 8)
DNA fiber-based replication phenotypes distinguish WEE1-inhibitor response in high-grade endometrial cancer patient-derived organoids (PDOs) treated with azenosertib (Presentation number 243)	Elena Ivanova, PhD	Poster Session: DNA Damage and Repair 1 – 2:00 pm - 5:00 pm PT (Section 11)
AI-driven structure-based drug discovery and validation of novel compounds as CTLA-4/B7 inhibitors (Presentation number 974)	Poonam Kalhotra, PhD	Poster Session: Computational, Technological, and Mechanistic Advances – 2:00 pm - 5:00 pm PT (Section 38)
Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC) (Presentation number 1020)	Stefania Morganti, MD	Poster Session: Biomarkers Predictive of Therapeutic Benefit 1 – 2:00 pm - 5:00 pm PT (Section 40)
Dynamic characterization of tumor-microenvironment factors that drive pediatric low-grade gliomas (Presentation number 632)	Jenna Robinson, PhD	Poster Session: Developmental Origins, Drivers, and Heterogeneity in Pediatric Cancer – 2:00 pm - 5:00 pm PT (Section 26)

Presentation	Author	Session/Time
Evaluation of an agentic LLM chatbot for clinico-genomic analysis of AACR GENIE BPC data (Presentation number 3)	Likhita Thiriveedi	Poster Session: AACR Project GENIE: Predictive Models and AI (Section 1) – 2:00 pm - 5:00 pm PT
The Kinase Library: A global atlas of the human protein kinome and its applications in cancer (Presentation number 1331)	Tomer Yaron-Barir, MD, PhD	Minisymposium: Innovative Targeted and Cellular Therapies for Exploiting Cancer Vulnerabilities – 3:00 pm - 5:00 pm PT
CTEP #10355 A phase 1 trial of DS-8201a and olaparib in HER2-expressing malignancies: Results from dose escalation (Presentation number CT035)	Elizabeth Lee, MD	Clinical Trials Plenary Session: Clinical Trials Plenary 2: Therapeutic Advances in ADCs – 3:30 pm - 5:30 pm PT
Monday, April 20, 2026		
Uptake of conservative management, and uptake of curative-intent treatment following conservative management, in low and favorable-intermediate risk prostate cancer patients (Presentation number 2346)	Isaac Allen, PhD	Poster Session: Epidemiology: Cancer Incidence, Mortality, Patterns, and Methodology – 9:00 am - 12:00 pm PT (Section 36)
Lethal progression risks of low risk and favorable-intermediate risk prostate cancer in a prospective cohort of US health professionals (Presentation number 2347)	Isaac Allen, PhD	Poster Session: Epidemiology: Cancer Incidence, Mortality, Patterns, and Methodology – 9:00 am - 12:00 pm PT (Section 36)
Modifiable lifestyle factors and immune gene expression in breast tumor and normal-adjacent tissue (Presentation number 2090)	Kristen Brantley, PhD	Poster Session: Aging and Host Determinants of Tumor Progression: The Macroenvironmental Axis – 9:00 am - 12:00 pm PT (Section 26)
Optimal epigenetic therapies in triple-negative breast cancer (Presentation number 1838)	Simone Bruno, PhD	Poster Session: Quantitative Pharmacology and Translational Modeling – 9:00 am - 12:00 pm PT (Section 17)
Integrating patient-derived tumor models into translational oncology and drug discovery (Presentation number 2178)	Cong Fu, PhD	Poster Session: In Vivo Models 1: Mouse, Zebrafish, and Alternative Species – 9:00 am - 12:00 pm PT (Section 29)
Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers (Presentation number 1850)	Antja-Voy Hartley, PhD	Poster Session: Targeting Drug Resistance 1: Apoptosis and Autophagy – 9:00 am - 12:00 pm PT (Section 18)
Immune-active and mesenchymal endothelial programs define TLS presence in the tumor microenvironment (Presentation number 2217)	Shoko Kure, MD	Poster Session: Tertiary Lymphoid Structures in Cancer – 9:00 am - 12:00 pm PT (Section 31)

Presentation	Author	Session/Time
Baseline single-cell mass distributions correlate with clinical response to acalabrutinib, venetoclax, and obinutuzumab in mantle cell lymphoma (Presentation number 2442)	Mingzeng Zhang, MD, PhD	Poster Session: Biomarkers Predictive of Therapeutic Benefit 3 – 9:00 am - 12:00 pm PT (Section 40)
The landscape of X chromosome copy number alterations in cancer (Presentation number 2002)	Matthew Leventhal, PhD	Poster Session: Genomic Drivers of Cancer Pathogenesis – 9:00 am - 12:00 pm PT (Section 23)
ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer (Presentation number 1783)	Na Zhang, PhD	Poster Session: Mechanisms of Drug Resistance 2 – 9:00 am - 12:00 pm PT (Section 16)
A real time imaging based functional precision medicine (FPM) assay for glioblastoma (Presentation number 2512)	Sonam Bhatia, PhD	Poster Session: Data-Driven Approaches to Precision Oncology – 9:00 am - 12:00 pm PT (Section 43)
Ciltacabtagene autoleucl in high-risk smoldering myeloma: Results from the CAR-PRISM trial (Presentation number CT103)	Omar Nadeem, MD	Clinical Trials Plenary Session: Clinical Trials Plenary 3: Cellular Therapies and Complex Immunotherapies – 10:15 am - 12:15 pm PT
Identifying and analyzing clinicopathological features of uterine endometrial endometrioid tumors discordant by p53 and copy number status (Presentation number 2677)	Sreekar Challa	Poster Session: Application of Bioinformatics to Cancer Biology 3 – 2:00 pm - 5:00 pm PT (Section 1)
Rewiring of pyruvate metabolism in neonatal CD8+ T cells alters functionality and antitumor immunity (Presentation number 3290)	Elinor DeCleene	Poster Session: Metabolic Studies in Brain, Pediatric, and Hematologic Cancers – 2:00 pm - 5:00 pm PT (Section 23)
Synergistic preclinical activity of dual CDK4/6 and mTORC1 inhibition in translocation renal cell carcinoma (Presentation number 3160)	Shikha Gupta, PhD	Poster Session: Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy – 2:00 pm - 5:00 pm PT (Section 18)
Immunomodulatory response in Dato-DXd-treated non-small cell lung cancer patient-derived organotypic tumor spheroids (pDOTS) (Presentation number 2830)	Patrick Hall Lizotte, PhD	Poster Session: Immune Mechanisms Invoked by Other Therapies and Exposures – 2:00 pm - 5:00 pm PT (Section 8)
LLM-based extraction of immunotherapy toxicities reveals severity-dependent effects on overall survival (Presentation number 2762)	Zeyun Lu, PhD	Poster Session: Large Language Models in the Clinic – 2:00 pm - 5:00 pm PT (Section 3)
Targeting the CD44-SPP1 axis to overcome therapy resistance in bladder cancer (Presentation number 3458)	Hiba Siddiqui	Poster Session: Microenvironmental Determinants of Therapy Response and Resistance 1 – 2:00 pm - 5:00 pm PT (Section 29)

Presentation	Author	Session/Time
Multi-omics analysis of longitudinal melanoma samples reveals evolutionary transitions and therapy-associated cell-state switching (Presentation number 3535)	Yourong Bao	Poster Session: Tumor Evolution – 2:00 pm - 5:00 pm PT (Section 33)
EED drives the small cell lung cancer neuroendocrine phenotype in lung cancer histological transformation (Presentation number 3528)	Yixiang Li, PhD	Poster Session: Tumor Evolution – 2:00 pm - 5:00 pm PT (Section 33)
Disrupted clock pathway during lineage plasticity and prostate cancer progression (Presentation number 2998)	Nishat Manzar, PhD	Poster Session: Molecular Targets 1 – 2:00 pm - 5:00 pm PT (Section 13)
Tumor mass dormancy - a potential driver of long-term persistent melanoma after immunotherapy? (Presentation number 3450)	Yingxiao Shi	Poster Session: Microenvironmental Determinants of Therapy Response and Resistance 1 – 2:00 pm - 5:00 pm PT (Section 29)
Urine cell-free DNA methylation-based deconvolution identifies tumor-specific cell types in localized urinary tract cancers (Presentation number 3848)	Ze Zhang, PhD	Poster Session: Liquid Biopsies: Circulating Nucleic Acids 3 – 2:00 pm - 5:00 pm PT (Section 45)
Tuesday, April 21, 2026		
Risk factors for early locoregional recurrence among young-onset breast cancer patients: Findings from a single institutional prospective dataset (Presentation number 5223)	Kristen Brantley, PhD	Poster Session: Biological and Clinical Consequences of Cancer Therapy – 9:00 am - 12:00 pm PT (Section 41)
Biodiversity and biogeography of the multi-kingdom cancer microbiome (Presentation number 4901)	Anders Dohlman, PhD	Poster Session: Microbiome-Tumor-Immune Crosstalk – 9:00 am - 12:00 pm PT (Section 29)
Targeting EGFR cysteine 775 in EGFR mutant lung cancer (Presentation number 5135)	Jie Jiang	Poster Session: New Ligands and Inhibitors – 9:00 am - 12:00 pm PT (Section 38)
Pan-cancer landscapes of transcriptional heterogeneity in metastatic tumors (Presentation number 4182)	Ramyar Molania, PhD	Poster Session: Integrative Computational Approaches 2 – 9:00 am - 12:00 pm PT (Section 4)
Reprogramming of the non-pathogenic E. coli surface architecture to create next-generation immune engagers for potent cancer therapies (Presentation number 4904)	Shaobo Yang, PhD	Poster Session: Microbiome-Tumor-Immune Crosstalk – 9:00 am - 12:00 pm PT (Section 29)

Presentation	Author	Session/Time
Targeting B7-H3 in the small cell lung carcinoma (SCLC) tumor-immune microenvironment (TIME) (Presentation number 5603)	Marco Campisi, PhD	Poster Session: T Cell Engagers 2 / Antibody-Drug Conjugates 1 – 2:00 pm - 5:00 pm PT (Section 8)
Investigating the transcriptomic signature of B7-H7-mediated activation of NK cell activity (Presentation number 6559)	Michael Gomez	Poster Session: Immune Checkpoint Blockade – 2:00 pm - 5:00 pm PT (Section 44)
Unraveling the missing heritability of unexplained familial cancers with germline genome sequencing (Presentation number 6278)	Noah Fields, MS	Poster Session: Genetic Epidemiology 2: Pathway Analysis, Sequencing, Functional Genetics / Family and Hereditary Studies – 2:00 pm - 5:00 pm PT (Section 34)
Exploring surface interactors promoting viability of CLL cells in contact with stromal fibroblasts (Presentation number 6045)	Uday Aditya Sarkar, PhD	Poster Session: Fibroblasts as Architects of the Tumor Microenvironment – 2:00 pm - 5:00 pm PT (Section 25)
Proliferative T cell infiltration is associated with colorectal cancer molecular subtypes and cancer specific survival (Presentation number 6571)	Yasutoshi Takashima, MD, PhD	Poster Session: Inflammation, Immunity, and Cancer – 2:00 pm - 5:00 pm PT (Section 45)
ccRCC lung metastases harbor cancer associated fibroblast lymphocyte exclusion sites that form a confined TME as revealed by single cell and spatial multi-omics (Presentation number 6113)	Yufei Wang, PhD	Poster Session: Metastasis and Organ-Specific Microenvironmental Evolution – 2:00 pm - 5:00 pm PT (Section 28)
Obesity shapes a reversible immune microenvironment that fosters breast cancer growth (Presentation number 6572)	Tao Zhang, PhD	Poster Session: Inflammation, Immunity, and Cancer – 2:00 pm - 5:00 pm PT (Section 45)
Results of a randomized placebo-controlled phase 2 study of metformin for the prevention of progression of precursor multiple myeloma (Presentation number CT254)	Catherine Marinac, PhD	Poster Session: Phase II Clinical Trials – 2:00 pm - 5:00 pm PT (Section 50)
Targeting non-enzymatic HDAC-mediated repression reveals a selective stress-adaptive mechanism for cancer therapy (Presentation number 6776)	Olivia Debnath, PhD	Minisymposium: Targeted Protein Degradation and Non-cannonical Oncogenic Signaling – 2:30 pm - 4:30 pm PT
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC) (Presentation number LB407)	Brian Wolpin, MD, MPH	Late-Breaking Minisymposium: Minisymposium: Late-Breaking Research – 2:30 pm - 4:30 pm PT

Presentation	Author	Session/Time
Wednesday, April 22, 2026		
Ganglioside targeting: Exerting sweet revenge on neuroblastoma (Presentation number 7814)	Guillermo Nicolas Dalton, PhD	Poster Session: Immunotherapies in Pediatric Cancers – 9:00 am - 12:00 pm PT (Section 44)
MBCproject: multi-omic profiling of metastatic breast cancer evolution through patient-partnered research (Presentation number 7265)	Diana Garcia-Cortes, PhD	Poster Session: Genomic Approaches to Define Tumor Biology and Clinical Stratification – 9:00 am - 12:00 pm PT (Section 21)
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding hub (Presentation number 7234)	Siddhant Jain, PhD	Poster Session: Chromatin Architecture and Regulatory Landscapes – 9:00 am - 12:00 pm PT (Section 20)
Pre-existing T cells drive durable anti-tumor immunity after oncolytic virus therapy in glioblastoma (Presentation number 7743)	Maxime Meylan, PhD	Poster Session: Immune Response to Therapies – 9:00 am - 12:00 pm PT (Section 42)
Tumor-intrinsic programs of epithelial-mesenchymal transition and immune deregulation are linked to disease recurrence in papillary thyroid carcinoma (Presentation number 7610)	Theodora Pappa, MD, PhD	Poster Session: Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers - 9:00 am - 12:00 pm PT (Section 35)